International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 383-389 , 1 October 2008

Feasibility of Using Bevacizumab With Radiation Therapy and Temozolomide in Newly Diagnosed High-Grade Glioma

  • Ashwatha Narayana, M.D.

      Affiliations

    • Department of Radiation Oncology, New York University Medical Center, New York, NY
    • Corresponding Author InformationReprint requests to: Ashwatha Narayana, M.D., Associate Professor, Department of Radiation Oncology, New York University Medical Center, 550 1st Avenue, New York, NY 11016. Tel: (212) 263-3729; Fax: (212) 263-2618
    • ,
  • John G. Golfinos, M.D.

      Affiliations

    • Department of Neurosurgery, New York University Medical Center, New York, NY
    • ,
  • Ingeborg Fischer, M.D.

      Affiliations

    • Department of Pathology, New York University Medical Center, New York, NY
    • ,
  • Shahzad Raza, M.D.

      Affiliations

    • Department of Radiation Oncology, New York University Medical Center, New York, NY
    • ,
  • Patrick Kelly, M.D.

      Affiliations

    • Department of Neurosurgery, New York University Medical Center, New York, NY
    • ,
  • Erik Parker, M.D.

      Affiliations

    • Department of Neurosurgery, New York University Medical Center, New York, NY
    • ,
  • Edmond A. Knopp, M.D.

      Affiliations

    • Department of Radiology, New York University Medical Center, New York, NY
    • ,
  • Praveen Medabalmi, M.P.H.

      Affiliations

    • Department of Bio-statistics, New York University Medical Center, New York, NY
    • ,
  • David Zagzag, M.D.

      Affiliations

    • Department of Pathology, New York University Medical Center, New York, NY
    • ,
  • Patricia Eagan, R.N.

      Affiliations

    • Department of Neuro-Oncology, New York University Medical Center, New York, NY
    • Atlantic Health System, Overlook Hospital, Summit, NJ
    • ,
  • Michael L. Gruber, M.D.

      Affiliations

    • Department of Neurosurgery, New York University Medical Center, New York, NY
    • Department of Neuro-Oncology, New York University Medical Center, New York, NY
    • Atlantic Health System, Overlook Hospital, Summit, NJ

Received 25 March 2008 ,Revised 16 May 2008 ,Accepted 17 May 2008.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Narayana A, Leibel SA. Primary and metastatic brain tumors in adults. In:  Leibel S,  Philips TL editor. Textbook of radiation oncology. 2nd ed.. Philadelphia, PA: Saunders; 2004;p. 471–495
  3. Mason WP, Cairncross JG. Drug insight: Temozolomide as a treatment for malignant glioma—Impact of a recent trial. Nat Clin Pract Neurol. 2005;1:88–95
  4. Stefanik DF, Fellows WK, Rizkalla LR, et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol. 2001;55:91–100
  5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  7. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am. 2007;21:303–319
  8. Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol. 2003;13:53–61
  9. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol. 2007;25:4714–4721
  10. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258–1260
  11. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729
  12. Narayana A, Kelly P, Golfinos J, et al. Anti-angiogenic therapy using bevacizumab in recurrent high grade glioma: Impact on local control and survival. J Neurosurg. 2008;In press
  13. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64:892–897
  14. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58:1215–1227
  15. Law M, Young RJ, Babb JS, et al. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490–498
  16. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280
  17. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182–1186
  18. Lamszus K, Ulbricht U, Matschke J, et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003;9:1399–1405
  19. Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev. 1998;17:241–248
  20. Jain RK. Normalizing tumor vasculature with ani-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001;7:987–989
  21. Glass J, Gruber LM, Nirenberg A. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. [Abstract] ASCO Proceedings. 1999;18:144a
  22. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–4085
  23. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708–715
  24. Takano S, Tsuboi K, Matsumura A, et al. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: Effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol. 2003;5:1–7
  25. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumors. Nat Rev Neurosci. 2007;8:610–622
  26. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60:353–357
  27. Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007;82:95–101
  28. Gutin P, Mohile N, Lymberis S, et al. Safety and efficacy of bevacizumab as a radiosensitizer in malignant glioma: Stereotactic re-irradiation for recurrences as a pilot for adjuvant treatment. [Abstract] J Clin Oncol. 2007;69(Suppl. 20):2028A
  29. Desjardins A, Barboriak DP, Herndon JE, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). [Abstract] J Clin Oncol. 2007;25(Suppl. 20):2029A
  30. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779–787
  31. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271–278
  32. Casanovas O, Hicklin D, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309

 Presented at the American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Los Angeles, CA, on October 31, 2007.

 Conflict of interest: none.

PII: S0360-3016(08)02455-3

doi: 10.1016/j.ijrobp.2008.05.062

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 383-389 , 1 October 2008

Article Tools

* Image Usage & Resolution